Novo Nordisk A/S (NVO) Expected to Announce Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) will likely be releasing its earnings data before the market opens on Wednesday, January 29th. Analysts expect Novo Nordisk A/S to post earnings of $0.88 per share for the quarter.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $87.45 on Tuesday. The business has a 50-day simple moving average of $95.35 and a 200 day simple moving average of $114.80. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $392.43 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 0.90 and a beta of 0.45.

Wall Street Analyst Weigh In

NVO has been the topic of a number of research reports. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.